22 results about "Bacillus ehimensis" patented technology

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention relates to the technical field of functional food, and particularly discloses a preparation method and application of origanum vulgare essential oil oral nanoemulsion, the preparation method comprises the following steps: by taking origanum vulgare essential oil as an oil phase, PEG-40 hydrogenated castor oil as a surfactant and propylene glycol as a cosurfactant, determining the mass ratio of the surfactant to the cosurfactant to be 5: 1 through optimization, and preparing the origanum vulgare essential oil oral nanoemulsion. And determining the final prescription composition by using the quasi-ternary phase diagram. The oregano essential oil oral nano-emulsion provided by the invention is a faint yellow transparent clarified liquid, is good in stability, has a remarkable bacteriostatic effect on staphylococcus aureus and escherichia coli, solves the problems of poor water solubility, poor stability and strong oral irritation of the oregano essential oil, and provides a good basis for the application of the oregano essential oil as an oral preparation.

The invention belongs to the technical field of microorganisms, and particularly relates to a bacterial strain for promoting formation of calculus bovis, a microbial agent and application of the bacterial strain, the bacterial strain is classified and named as Escherichia fergusonii, the bacterial strain is preserved in China General Microbiological Culture Collection Center on May 13, 2025, and the preservation number is CGMCC No.34526. The invention further discloses a preparation method of the bacterial strain for promoting formation of calculus bovis. The strain can be used as a transformation strain for in-vitro cultivation of calculus bovis and can also be used as an implantation strain for artificial in-vivo cultivation of calculus bovis, and the problems that in the process of artificial in-vitro cultivation or in-vivo cultivation of calculus bovis, thalli are low in bile tolerance and enzyme production activity, short in survival time in ox bile and low in calculus bovis forming efficiency are solved.

The invention discloses an application of a strobilanthes guineensis extract in bacteriostasis, and belongs to the technical field of traditional Chinese medicine extraction, and the strains capable of being inhibited comprise bacillus subtilis, staphylococcus aureus, pseudomonas aeruginosa and escherichia coli; the strobilanthes laxiflora extract comprises a water extract, a water extraction and alcohol precipitation extract and a chloroform extract according to different extraction modes; according to the invention, it is proved that the lauberine has an inhibition effect on bacillus subtilis, staphylococcus aureus, pseudomonas aeruginosa and escherichia coli, has a certain antibacterial effect, and provides a reference basis for further research on the antibacterial activity of the lauberine.

The invention belongs to the technical field of microorganisms, and particularly relates to Escherichia coli MZ2014 with sustainable phenotypic heterogeneity and heterogeneity drug resistance characteristics and application of the Escherichia coli MZ2014. The MZ2014 strain can be continuously and stably differentiated into two forms of a large bacterial colony (MZ2014-B) and a small bacterial colony (MZ2014-S) under conventional culture conditions, and the two subgroups show a clear heterogeneity drug-resistant phenotype: the MZ2014-B is shown as a medium for ertapenem, and the MZ2014-S is shown as sensitivity. Further researches show that the two subgroups have significant differences in cellular morphology, growth rate and athletic ability. Therefore, the MZ2014 strain provided by the invention is not only a precious model for researching phenotypic heterogeneity and non-hereditary drug resistance mechanisms, but also can be used as a key tool for screening active substances capable of overcoming heterogeneity drug resistance or inhibiting phenotypic differentiation, and has important scientific research value and application prospect.

The application discloses a bacteriophage cocktail for treating or preventing high-risk clonal strains of companion animals and application thereof. The application provides a bacteriophage cocktail containing bacteriophages 32M3Y, CRE5643Y, 3BB6Y and S17S. Through simulating the mechanism of resistance occurrence in the bacteriophage treatment process, the second round of bacteriophage screening is carried out on the bacteriophage-resistant strains. The obtained candidate bacteriophages can lyse the resistant strains of high-risk clonal strains of Escherichia coli. The composition composed of the candidate bacteriophages can inhibit the resistance evolution of the bacteria in the bacteriophage treatment process, can avoid the emergence of the bacteriophage-resistant strains with enhanced virulence in the bacteriophage treatment process, has the effect of preventing and treating pet clinical ST410 type strain infection, and can be used for environmental disinfection. Through blocking the transmission chain of drug-resistant bacteria in the domestic environment (pets-human-environment), the risk of human-animal coexistence can be significantly reduced.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

This invention belongs to the field of microbial technology, specifically relating to the multifunctional Lactobacillus curvatureii and its application in the preparation of health products. The Lactobacillus curvatureii (… Lactobacillus crispatus Lactobacillus crispatus The accession number for MCOlact00102 is CGMCC No. 34381. The described *Lactobacillus curvatureensis* (MCOlact00102) is... Lactobacillus crispatus ​ The two strains, MCOlact00126 (CGMCC No. 34382), exhibit significant inhibitory effects against bacterial vaginosis (BV) and infections caused by Gardnerella vaginalis, Group B Streptococcus (GBS), Escherichia coli, or Candida albicans. The safety of these strains was evaluated using a 3D vaginal epithelial organoid model, showing no irritant effect on cells. Furthermore, hemolytic activity tests, antibiotic resistance gene detection, and functional validation all demonstrated their good safety profile. In addition, the aerobic acclimation process significantly improved the stability and bioactivity of these two strains in actual production and clinical applications, laying a solid foundation for their industrialization and application.

The invention relates to the technical field of conjugational transfer engineering bacteria, in particular to a conjugational transfer donor bacterium as well as a construction method and application thereof, the conjugational transfer donor bacterium is Escherichia fergusonii EFmg-sy, is preserved in the China Center for Type Culture Collection (CCTCC), and has the preservation number of CCTCC NO: M2025310; the invention relates to a conjugational transfer donor bacterium which is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of CCTCC NO: M20251730, or the conjugational transfer donor bacterium is Escherichia fergusonii EFmg-cj and is preserved in China Center for Type Culture Collection (CCTCC). The conjugational metastasis donor bacterium provided by the invention is stable in character, is simple to operate as a conjugational metastasis donor, and can be used for rapidly detecting and distinguishing the conjugational metastasis donor bacterium and a recipient bacterium receiving plasmids through a fluorescence detection method, so that the detection of the plasmid horizontal transfer capability of the Escherichia fjosenii is realized.

The application discloses a solubilization-stable liquid preparation of Trollius chinensis Bunge and a preparation method thereof. Anionic surfactant is used as a micelle carrier. Through a stable micelle structure formed in the water phase, the poorly soluble active ingredients in Trollius chinensis Bunge extract are dissolved and uniformly dispersed in the water phase, so that the solubility and system stability are significantly improved, and the bacteriostatic effect is improved. Through screening of formula components and optimization and adjustment of the composition ratio, the application successfully prepares a clear liquid preparation with excellent bacteriostatic activity from the poorly soluble substances of Trollius chinensis Bunge. The inhibition rate of the preparation on Escherichia coli, Staphylococcus aureus and Candida albicans is more than 90% after 30s of contact. The preparation has good stability after being placed at room temperature for 24 months, and the inhibition rate on the three test bacteria is still more than 80%. The concentration of Trollius chinensis Bunge extract required to achieve the same or even better bacteriostatic effect is far lower than 1 / 16 of the Trollius chinensis Bunge liquid preparation assisted by dimethyl sulfoxide (DMSO) organic solvent.

This invention discloses an antimicrobial 10-peptide, characterized by the sequence: w-k-r-w-r-r-w-w-r-r(dTrp-dLys-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dArg), where all amino acids are D-type amino acids. The antimicrobial peptide provided by this invention exhibits good antimicrobial activity against a variety of pathogenic bacteria. This antimicrobial peptide can be synthesized using the Fmoc solid-phase chemical method, which is easy to synthesize and exhibits good in vivo antimicrobial activity. This antimicrobial peptide exhibits broad-spectrum killing activity against multidrug-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, as well as standard strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus. It has low hemolytic toxicity, and at low to medium concentrations (2 μg / mL to 32 μg / mL), the cell survival rate can reach more than 50%. It has no toxic effect on cells, good stability, strong operability, and low cost.

The invention relates to the technical field of biology, in particular to a rapid detection kit for bacterial food-borne pathogenic microorganisms and application of the rapid detection kit. The invention develops a primer probe combination kit for detecting food-borne bacteria salmonella, staphylococcus aureus, vibrio parahaemolyticus, listeria monocytogenes, escherichia coli O157 and clostridium perfringens through optimization of primers, optimization of hydrogel components and a system and the like. The primer probe combination kit is used for detecting food-borne bacteria salmonella, staphylococcus aureus, vibrio parahaemolyticus, listeria monocytogenes, escherichia coli O157 and clostridium perfringens. The kit is used for detecting salmonella, staphylococcus aureus, vibrio parahaemolyticus, listeria monocytogenes, Escherichia coli O157 and clostridium perfringens. The kit is high in sensitivity and specificity, strong in anti-interference capability, excellent in stability and portability, rapid and efficient in detection, simple and convenient to operate and low in cost, and can realize result visualization and relative quantification, so that the kit has wide application prospects and values.

The invention belongs to the technical field of microbiology and medicine, and particularly relates to application of a bacterial growth regulator to regulation of clinical bacterial growth. The invention provides a novel bacterium growth regulator, namely sodium hydrosulfide (NaHS), and discloses a remarkable and complex bidirectional regulation effect of the sodium hydrosulfide on in-vitro growth of various clinically common gram-positive and gram-negative bacteria, and the sodium hydrosulfide can effectively inhibit growth of common gram-positive cocci and also can inhibit growth of common gram-negative cocci. The compound also shows a growth promoting effect on gram-negative enterobacter klebsiella pneumoniae and escherichia coli, and the promoting effect is proved through colony counting and dynamic growth curve monitoring. The discovery reveals the unique potential of the regulator as a bacterial growth regulation tool, and the regulator has important clinical application value.

The application belongs to the technical field of microorganisms, and particularly relates to a fermented Lactobacillus muci genus with high efficient bacteriostatic and biofilm inhibiting capacity and application of a product of the fermented Lactobacillus muci genus in preparation of health products. Limosilactobacillus fermentum ​ ) H57-AN-Na1-4 is preserved as CGMCC No. 35329. The fermented Lactobacillus muci genus of the application has a significant inhibiting effect on Gardnerella, Streptococcus group B, Escherichia coli, Staphylococcus aureus and Candida albicans infection and also has a good inhibiting capacity on biofilms of the pathogenic bacteria, thereby reducing the infection risk. The fermented Lactobacillus muci genus can be used for preventing or treating diseases related to the infection of the pathogenic bacteria. The fermented Lactobacillus muci genus of the application has a high lactic acid production, promotes a healthy microecological environment, has superior cell colonization capacity and enhances the bacteriostatic effect. In addition, the safety of the fermented Lactobacillus muci genus of the application is jointly proved by hemolytic test, antibiotic resistance gene detection and functional verification.

The invention discloses a lactobacillus reuteri and a preparation method and application of a microbial inoculum of the lactobacillus reuteri, the lactobacillus reuteri subsp.reuteri OH114 is preserved in Guangdong Province Microbial Culture Collection Center (GDMCC), the preservation address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No.66528, and the preservation time is June 16, 2025. The lactobacillus reuteri newly researched and developed by the invention can effectively inhibit the growth of a plurality of enteropathogenic bacteria such as staphylococcus aureus, escherichia coli, salmonella typhimurium, clostridium difficile, clostridium perfringens, klebsiella pneumoniae, pseudomonas aeruginosa and candida albicans, regulate the balance of intestinal flora, prevent and treat adult diarrhea, and prevent and treat diarrhea. The invention provides a new scheme and way for preventing and treating infectious diarrhea, antibiotic-related diarrhea or irritable bowel syndrome diarrhea.

The invention belongs to the technical field of bacteriostatic agents and application thereof, and particularly relates to a Tibetan medicine composition, a preparation method and application of the Tibetan medicine composition in bacteriostatic products. The traditional Tibetan medicine sophora moorcroftiana seeds, cortex phellodendri, myricaria laxiflora and artemisia sieversiana are compounded, active ingredients in the traditional Tibetan medicine sophora moorcroftiana seeds, cortex phellodendri, myricaria laxiflora and artemisia sieversiana are extracted, the water-soluble plant source bacteriostatic agent with a good bacteriostatic effect is prepared, and the alkaloid content in the obtained bacteriostatic agent is 2.06-2.78 mg / g by optimizing an extraction process; in addition, the Tibetan medicine composition provided by the invention has a good inhibition effect on ten microbial bacteria such as escherichia coli, candida albicans, staphylococcus aureus, bacillus subtilis, propionibacterium acnes, streptococcus mutans, salmonella enteritidis, pseudomonas aeruginosa, porphyromonas gingivalis and staphylococcus epidermidis, and has universal antibacterial activity; the method can be widely applied to antibacterial products in various fields.

The present application relates to the technical field of conjugative transfer engineering bacteria, and relates to a conjugative transfer donor bacterium, a construction method and application thereof, the conjugative transfer donor bacterium is Escherichia fergusonii EFmg-sy, which is preserved in China Center for Type Culture Collection, and the preservation number is CCTCC NO:M2025310;Or, the conjugative transfer donor bacterium is Escherichia fergusonii EFmg-cj, which is preserved in China Center for Type Culture Collection, and the preservation number is CCTCC NO:M20251730.The conjugative transfer donor bacterium provided by the present application is stable in property, simple in operation as a conjugative transfer donor, can be quickly detected and distinguished from the receptor bacterium that has received plasmid through the method of fluorescence detection, and the detection of the plasmid horizontal transfer ability of Escherichia fergusonii is realized.

This invention discloses a method for preparing a strain of Lactobacillus saccharidus and its application in the preservation of chilled fresh meat, including the following steps: Step (1) Initial screening: Take 1.0 g of environmental sample, add 9 mL of sterile physiological saline, shake at 37℃ and 200 r / min for 30 min, sonicate for 10 min, then serially dilute to 10⁻⁴-10⁻⁶, take 100 μL and spread it on MRS solid medium, incubate at 37℃ for 48 h, pick single colonies and purify 3 times; Step (2) Antibacterial screening: Use 8 strains of putrefactive bacteria such as Enterobacter and Escherichia coli as indicator bacteria. The preparation method of this Lactobacillus saccharidus strain is based on natural sources, ensuring high safety and making it a suitable alternative to chemical preservatives. It exhibits significant inhibitory effects on major spoilage bacteria (such as Pseudomonas and Enterobacteriaceae) and pathogenic bacteria in chilled meat. Its low-temperature resistance (4℃) and acid and alkali resistance make it suitable for the storage environment of chilled meat. After application, it can reduce the total bacterial count, TVB-N content, pH value, and drip loss rate, delay color changes, and effectively extend the shelf life of chilled meat.

The present application relates to the technical field of microfluidics, and particularly relates to a kit for rapidly detecting 15 respiratory pathogens and a use method thereof.The kit comprises a plurality of reaction cavities, each of which has a primer group corresponding to 15 respiratory pathogens; the primer group comprises inner primers, outer primers and loop primers for PCR amplification of Mycoplasma pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Stenotrophomonas maltophilia, Haemophilus influenzae, Streptococcus pneumoniae, Escherichia coli, Legionella pneumophila, Burkholderia, Staphylococcus aureus, Corynebacterium striatum, Aspergillus, Pneumocystis jirovecii and Candida albicans.The present application can simultaneously detect 15 respiratory pathogens by adding samples once, avoids adding liquid reagents to multiple detection tubes, reduces the intensity of manual operation and the risk of mismatch.

The application provides a chaetomium globosum, a method for separating secondary metabolites of the chaetomium globosum and application, and belongs to the technical field of biological medicines. Arcopilus cupreus DGR-7 has been preserved in Guangdong Microbial Culture Collection Center on October 10, 2025, with a preservation number of GDMCC No: 67068; the application first utilizes rice medium to ferment A. cupreus strains, and 8 compounds are separated and purified from the strains, wherein 6 compounds are anthraquinones. In-vitro antibacterial experiments show that the chaetomium globosum Arcopilus cupreus The secondary metabolites of DGR-7, anthraquinones, have good bioactivity in inhibiting the growth of staphylococcus aureus, methicillin-resistant staphylococcus aureus, streptococcus salivarius, klebsiella pneumoniae, bauman acinetobacter, pseudomonas aeruginosa and escherichia coli.

The invention provides chaetomium hordeum, a method for separating secondary metabolites from chaetomium hordeum and application of the chaetomium hordeum, and belongs to the technical field of biological medicine. The chaetomium cupreum DGR-7 is preserved in the Guangdong Microbial Culture Collection Center on October 10, 2025, and the preservation number of the chaetomium cupreum DGR-7 is GDMCC No: 67068; according to the invention, the rice culture medium is used for fermenting the A.cupreus strain for the first time, and the A.cupreus strain is separated and purified to obtain 8 compounds, including 6 anthraquinone compounds. An in-vitro antibacterial experiment shows that the secondary metabolite anthraquinone compound of the Arcoporus cupreus DGR-7 has good biological activity in the aspect of inhibiting the growth of staphylococcus aureus, methoxyl-resistant staphylococcus aureus, streptococcus salivarius, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa and escherichia coli.